rates

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…

11 months ago

Manufacturers and Logistics Providers Embrace AI for Enhanced Barcode Reading Performance

Survey reveals 90% of users anticipate AI will improve accuracy, ease of use, decode rates, and more NATICK, Mass., June…

12 months ago
Show previous Posts